Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)

A Single Arm, Open-label Phase II Study to Evaluate the Efficacy and Safety of Capecitabine Plus Oxaliplatin (XELOX) in the Peri-operative Treatment of Patients With Potentially Resectable Liver Metastasis From Colorectal Cancer

This is a single arm, open-label phase II study to evaluate the efficacy and safety of Capecitabine plus oxaliplatin (XELOX) in the peri-operative treatment of patients with potentially resectable liver metastasis from colorectal cancer.

To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer

Inclusion Criteria:

• Age of 18 and 65
• Histologically confirmed colorectal cancer and two methords of imaging detection confirmed liver metastasis
• Potentially curable by resection, as determined by a surgeon with hepatic surgery expertise
• No evidence of extrahepatic disease by chest x-ray or CT scan of the chest, abdomen, and pelvis
• Patients with adequate hepative, renal and bone marrow function
• Signed written informed consent

Exclusion Criteria:

• Pregnant or nursing patients (fertile patients must use effective contraception)
• Other malignancy within the past 5 years except completely resected nonmelanoma skin cancer or carcinoma in situ of the cervix
• Preexisting grade 2 or greater peripheral neuropathy
• Concurrent uncontrolled illness
• Ongoing or active infection
• Psychiatric illness or social situation that would preclude study compliance
• Less than 6 months since prior adjuvant fluorouracil-based chemotherapy
• Prior chemotherapy for liver metastasis
• Prior oxaliplatin for colorectal cancer
• Prior or concurrent hepatic artery infusion chemotherapy for metastatic disease
• Prior or concurrent radiotherapy for metastatic disease
• Prior or concurrent radiofrequency ablation for metastatic disease
• concurrent treatment with any other anti-cancer therapy.